#USA #New York #Lung Cancer #Innovation Gala #Raymond Chalmé

Lung Cancer Research Foundation Honors Leaders in Research at 2025 Evening of Innovation Gala

The Lung Cancer Research Foundation (LCRF) is readying for its 4th Annual Evening of Innovation Gala to take place on September 17, 2025, at Cipriani 25 Broadway in New York City. This event is set to recognize distinguished contributors to the field of lung cancer research, featuring Raymond E. Chalmé and Dr. Joan H. Schiller as honorees, alongside AstraZeneca receiving the Corporate Honoree designation.

Raymond E. Chalmé, a dedicated member of LCRF's Board of Directors for nearly twenty years, will be acknowledged for his transformative impact on lung cancer research and his humanitarian endeavors. He co-founded Elliot's Legacy Kites for a Cure, a fundraising event inspired by his late father, Elliot Chalmé, who succumbed to lung cancer at 56. The annual event has remarkably raised more than $8 million, contributing to nearly $50 million in additional research funding.

Aubrey Rhodes, Executive Director of LCRF, remarked, "Ray's commitment to lung cancer research is immeasurable. He inspires others to join the mission of curing lung cancer through research." Chalmé himself expressed immense gratitude at receiving this honor, stating how rewarding it is to have played a role in improving survival rates through research initiatives. “When we commenced Elliot's Legacy, survival from lung cancer was nearly impossible. Today, not only are rates climbing, but many of my fellow board members embody the progress achieved through strategic research efforts. This honor further fuels my family's commitment to continue advocating for lung cancer research,” Chalmé shared.

Equally distinguished is Dr. Joan H. Schiller, who will be presented with the Founders Award for her lifelong dedication to lung cancer research and her unwavering commitment to patients. As the founder and president of Free to Breathe, Dr. Schiller has mobilized significant support for lung cancer research and has been a key voice advocating for organized, private funding in this critical area. Her contributions extend beyond her role as a researcher and clinician, as she actively serves on LCRF's Board of Directors and has championed initiatives focused on the confluence of climate change and lung health.

Mary Ann Tighe, a fellow LCRF Board Member, lauded Chalmé’s contributions while emphasizing the importance of Dr. Schiller’s pioneering work that has laid the groundwork for many current lung cancer initiatives. “Her leadership has been instrumental in guiding LCRF's respected research programs. Both Ray and Joan’s recognition at the gala highlights the relentless strides we are making in lung cancer research,” she added.

AstraZeneca’s U.S. Medical Franchise Head for Lung Cancer, Nabil Chebab, expressed pride in being recognized as the Corporate Honoree. Chebab stated, “We stand shoulder to shoulder with champions of lung cancer advocacy like Ray Chalmé and Dr. Schiller, and we're dedicated to enhancing the lives of lung cancer patients through innovation in research, advocacy, and industry.”

The Evening of Innovation gala will begin at 6 PM, presenting an opportunity for guests to engage with individuals whose lives have been changed through the work of LCRF, as well as to understand how they can contribute to the ongoing fight against lung cancer.

To learn more about the Lung Cancer Research Foundation and the impact of the Evening of Innovation Gala, visit LCRF.org/gala.

About the Lung Cancer Research Foundation (LCRF)

The Lung Cancer Research Foundation is a leading nonprofit organization focused on advancing innovative research aimed at improving survival and quality of life for those affected by lung cancer. As of now, they have funded 429 research grants totaling nearly $48 million, making them the foremost nonprofit backing lung cancer research. For further information, please explore their website at LCRF.org.